---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-001416"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:30:12.288440+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio reports Phase 1 data for ELI-002: 84% T cell response, 16.3-month median RFS

## Summary
- AMPLIFY-201 data published in Nature Medicine in 25 patients (20 pancreatic, 5 colorectal) with minimal residual mKRAS disease.
- ELI-002 induced direct ex vivo mKRAS-specific T cell responses in 84% of patients; 59% both CD4+ and CD8+.
- 84% of patients had tumor biomarker reduction; 24% achieved complete biomarker clearance.
- Median relapse-free survival was 16.33 months; high T cell responders had 86% reduction in risk of progression or death.
- Phase 2 monotherapy trial in pancreatic ductal adenocarcinoma planned to start early 2024; no safety concerns identified.

## SEC filing metadata
- accession: 0001140361-24-001416
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000114036124001416/0001140361-24-001416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000114036124001416/ef20018418_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-001416
- JSON: https://secwatch.observer/filing/0001140361-24-001416.json
- Plain text: https://secwatch.observer/filing/0001140361-24-001416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.